RVV: lower costs, faster-time-to-market, and exclusivity“As part of our pharmaceutical strategy, we are focusing our efforts on developing unique cannabis-based therapies for rare diseases,” said Fabio Chianelli, President of Revive. “We are pursuing strategies that we believe will result in lower development costs, faster-time-to-market, and market exclusivity for our cannabis-based pharmaceutical products. We believe by securing patent protection and/or orphan drug status, and establishing proof-of-concept in validated pre-clinical models may expedite the clinical development and regulatory pathway of our products and pave the way for partnering with pharmaceutical companies and licensed producers of medical cannabis.”